Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Cassava Sciences Is Having a Bad Day

By Cory Renauer – Updated Aug 31, 2021 at 3:55PM

Key Points

  • The FDA recently received a citizen petition regarding simufilam from a law firm known for class-action suits against publicly traded companies.
  • The allegations center around heavy reliance on a single academic laboratory for positive data regarding simufilam.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA received a citizen petition requesting a halt to clinical trials with the company's Alzheimer's disease candidate.

Editor's Note: This article was updated on Aug. 31 to reflect that Labaton Sucharow was representing clients with short positions in Cassava Sciences when it filed the citizen petition filed with the FDA.

What happened

Cassava Sciences (SAVA -1.17%) stock started Wednesday in the dumps after responding to a citizen petition that the Food and Drug Administration acknowledged on Monday. The petition was filed by law firm Labaton Sucharow, which said in an Aug. 26 press release that it represented clients who have short positions in Cassava Sciences. Shares of the clinical-stage drugmaker were down 21% as of 10:55 a.m. EDT on Wednesday.

So what 

As a pre-commercial company without any revenue yet, all eyes are on its Alzheimer's disease candidate called simufilam. Since this is the company's only new drug candidate in clinical trials, news of any potential problem can lead to swift and heavy losses.

A person looks at their phone.

Image source: Getty Images.

Cassava Sciences is tanking today in response to a citizen petition asking the FDA to halt all ongoing studies with simufilam while the agency verifies data the company has submitted so far.

The most troubling allegations from the short sellers via the law firm concern heavy reliance on a single academic laboratory run by Dr. Hoau Yan Wang at the City University of New York. According to the allegations, Wang's laboratory is the only source outside of the company to confirm the foundational science supporting Cassava's claims. This includes a phase 2 biomarker study that failed miserably when patient samples were run by a lab that wasn't Wang's. The same samples ended up producing compelling data once measured again by an unnamed academic laboratory assumed to be Wang's.

Now what

On Wednesday, Cassava Sciences responded to many of Labaton Sucharow's allegations. In the long list of denials, though, the company didn't explain its apparent dependence on Wang's laboratory for positive data.

Cassava Sciences' contribution to neuroscience before simufilam is limited to an abuse-deterrent version of oxycodone called Remoxy that the FDA refused to approve in 2018. It's hard to imagine a company that couldn't get a new version of an old pain drug past the FDA cracking the Alzheimer's code on its first real attempt at neuroscience. It's probably a good idea to watch this biotech's story play out from the sidelines.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cassava Sciences, Inc. Stock Quote
Cassava Sciences, Inc.
SAVA
$34.51 (-1.17%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.